2. Antibodies
  3. Primary Antibodies
  4. Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies
  5. MLH1 Antibody (YA290)

MLH1 Antibody (YA290) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MLH1.

For research use only. We do not sell to patients.

Size Price Stock Quantity
20 μL Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks
50 μL Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks
100 μL Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks
250 μL   Get quote  
Synthetic products have potential research and development risk.
or Bulk Inquiry

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • WB: Western Blot;
  • IHC-P: Immunohistochemistry-Paraffin;
  • IHC-F: Immunohistochemistry-Frozen;
  • ICC/IF: Immunocytochemistry/Immunofluorescence;
  • IF-Tissue: Immunofluorescence-Tissue;
  • mIHC: Multiplex Immunohistochemical;
  • IP: Immunoprecipitation;
  • ChIP: Chromatin Immunoprecipitation;
  • FC: Flow Cytometry;
  • ELISA: Enzyme Linked Immunosorbent Assay

  • Product Detail

  • Background

  • Documentation

  • References

Description

MLH1 Antibody (YA290) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MLH1.
Host

Rabbit
Clonality

Recombinant, Monoclonal
Molecular Weight
Predicted band size: 85 kDa;
Observed band size: 85 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Species Reactivity
Human, Mouse, Rat
SwissProt ID
Gene ID
Immunogen

Synthetic peptide corresponding to Human MLH1.AA range:707-756.
Application &
Dilution Ratio
Application Dilution Ratio
WB
WB: Western Blot
1:500-1:1000
ICC/IF
ICC/IF: Immunocytochemistry/Immunofluorescence
1:50-1:200
IHC-P
IHC-P: Immunohistochemistry-Paraffin
1:50-1:200
FC
FC: Flow Cytometry
1:50-1:100
IP
IP: Immunoprecipitation
Use at an assay dependent concentration.
Sensitivity Endogenous Purity Protein A affinity purified.
Conjugation Non-conjugated Modification Unmodified
Isotype IgG  
Appearance

Liquid
Formulation

Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.
Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
Shipping

Shipping with blue ice.
Background
Function：Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis
Subcellular Localization：Nucleus; Chromosome
Expression：
Tissue_specificity:Colon, lymphocytes, breast, lungs, spleen, testes, prostate, thyroid, gallbladder, and heart
Subunit：Component of the DNA mismatch repair (MMR) complex composed at least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex (PubMed:10783165). This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). Interacts with PMS2; this interaction promotes MLH1 stability (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). Interacts with MTMR15/FAN1 (PubMed:20603073)
Database

Entrez Gene: 4292 Human ; 17350 Mouse ; 81685 Rat

SwissProt: P40692 Human ; Q9JK91 Mouse ; P97679 Rat

OMIM: 609310 Human

Research Field

Epigenetics and Nuclear Signaling
Documentation
User Guide for Antibodies (1077 KB)
References

MLH1 Antibody (YA290) Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MLH1 Antibody (YA290)
Cat. No.:
HY-P80226
Quantity:
MCE Japan Authorized Agent:

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Country or Region *

Email Address *

     

Phone Number *

 

Organization Name *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.